5+ mon, 2+ week ago   (107+ words) Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from…...

3+ mon, 1+ week ago   (510+ words) The Poison Pill defends against no legitimate threat; 3D's acquisition of additional shares is not aimed at seizing management control, nor does it impair corporate value or the common interests of shareholders. The Board lacks the sufficient independence required to…...

3+ mon, 2+ week ago   (155+ words) Dr. Ran Rubinstein introduces BioRePeel to both New York and New Jersey practices as demand grows for no-downtime skin rejuvenation treatments. A New Option for Patients Who Want Results Without the Downtime What Sets BioRePeel Apart A Peel That Fits…...

4+ mon, 6+ day ago   (100+ words) Date and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time. Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 273453. Replay: A teleconference replay of the call…...

3+ mon, 2+ week ago   (507+ words) Median is a leading provider of imaging services to the world’s top oncology pharma companiesMedian will host two presentation sessions to introduce its new solutions for radiopharmaceutical image processing and cachexia assessment for oncology research at booth #36102SOPHIA ANTIPOLIS, France--(BUSINESS…...

3+ mon, 2+ week ago   (767+ words) Pharmaceutical service provider receives prestigious management award for the seventh year in a rowFamily-owned company once again excels in all four key business areasSite development and digitalization as strategic investment prioritiesFocus on new sources for skilled workers and on lifelong…...

3+ mon, 2+ week ago   (739+ words) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert…...

3+ mon, 2+ week ago   (604+ words) Zurich, May 26, 2026 – MetrioPharm AG, a clinical-stage biotechnology company developing medicines for inflammatory and infectious diseases, today announced that Prof. Dr. med. Jürgen Braun is joining the company’s Scientific Advisory Board. With the appointment of Prof. Braun, MetrioPharm is specifically expanding…...

3+ mon, 3+ week ago   (624+ words) Opinion granted based on positive event-free survival, overall survival and pathologic complete response rate results from the Phase 3 KEYNOTE-905 trial If approved, this combination would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen for this patient population…...

3+ mon, 3+ week ago   (60+ words) – Acquisition Builds on Gilead’s Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform – About TUB-040 and the Tubutecan Technology About Gilead and Kite Oncology Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its…...